Foundayo Side Effects: What to Expect
Every reaction the orforglipron trial program recorded, alongside the boxed warning and the Section 5 risks its FDA label carries.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Reaction rates and warnings here are read from the FDA label for Foundayo. Most of what a GLP-1 produces is gut-related and peaks in the days after a dose goes up, so the Foundayo dosing page shows where each step falls. The Foundayo drug guide covers the rest of the drug.
Most Common Foundayo Side Effects
Every reaction the Foundayo FDA label records, showing how often it appeared among orforglipron-treated patients and how often it appeared on placebo. The figures are taken from the label's Section 6, DailyMed SetID8ac446c5-feba-474f-a103-23facb9b5c62.
| Adverse reaction | Incidence (Foundayo vs placebo) |
|---|---|
| Nausea | 26–35% (placebo 10%) |
| Constipation | 20–27% (placebo 9%) |
| Diarrhea | 21–25% (placebo 11%) |
| Vomiting | 13–24% (placebo 4%) |
| Dyspepsia | 12–16% (placebo 4%) |
| Abdominal pain | 13–14% (placebo 7%) |
| Headache | 8–9% (placebo 7%) |
| Abdominal distension | 7–9% (placebo 3%) |
| Fatigue | 6–9% (placebo 4%) |
| Eructation | 6–8% (placebo 1%) |
| Gastroesophageal reflux disease | 6–7% (placebo 2%) |
| Flatulence | 5–6% (placebo 2%) |
| Hair loss | 4–5% (placebo 2%) |
Source: Foundayo FDA prescribing information via DailyMed (SetID 8ac446c5-feba-474f-a103-23facb9b5c62), Section 6 Adverse Reactions, read on 2026-09-27. Treat this as a summary — the full label is the document, and a prescriber is the person to discuss it with.
Boxed Warning — Thyroid C-Cell Tumors
“In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined. FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”
Quoted word for word from the Foundayo FDA label (DailyMed SetID 8ac446c5-feba-474f-a103-23facb9b5c62). Nothing the FDA issues carries more weight than a boxed warning. Your own history and your family's both need to be on the table before you start Foundayo, and that means talking to a licensed prescriber.
Serious Warnings & Precautions
Past the everyday reactions above, Section 5 of the Foundayo label sets out these serious risks. They arrive far less often, and some of them need care the same day — which is why the symptoms are worth knowing and when to seek care.
- Risk of thyroid C-cell tumors
- Acute pancreatitis
- Severe gastrointestinal reactions
- Acute kidney injury due to volume depletion
- Hypoglycemia
- Hypersensitivity reactions
- Diabetic retinopathy complications in patients with type 2 diabetes
- Acute gallbladder disease
- Pulmonary aspiration during general anesthesia or deep sedation
Compare every Foundayo provider
Every warning above is something a prescriber screens for before writing anything. Current price, verification status, product form and the states each seller ships to are all on one screen.
Related deep-dives
What to do about each symptom, and the evidence underneath it, is covered here: